Consumer medicine information

Flamazine Cream

Silver sulfadiazine

BRAND INFORMATION

Brand name

Flamazine

Active ingredient

Silver sulfadiazine

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Flamazine Cream.

SUMMARY CMI

Flamazine™

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using Flamazine?

Flamazine contains the active ingredient silver sulfadiazine. Flamazine is used to prevent infection in severe burns. For more information, see Section 1. Why am I using Flamazine? in the full CMI.

2. What should I know before I use Flamazine?

Do not use if you have ever had an allergic reaction to silver sulfadiazine or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, have any allergies to any other medicines or any other substances, are glucose-6-phosphate deficient, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before I use Flamazine? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with Flamazine and affect how it works. For more information, see Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use Flamazine?

  • Flamazine should be applied by means of a sterile spatula or by hand, covered with a sterile glove, in a layer approximately 3-5 mm thick.
  • One application at least every 24 hours is normally sufficient but the number of times a day to apply the cream will depend on your own individual needs
  • Where necessary reapply Flamazine to any area where it has been removed during activity.

More instructions can be found in Section 4. How do I use Flamazine? in the full CMI.

5. What should I know while using Flamazine?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using Flamazine
  • If you feel that Flamazine is not helping your condition, tell your doctor (or pharmacist)
  • Tell your doctor if, for any reason, you have not used Flamazine exactly as prescribed
Things you should not do
  • Do not use Flamazine in or near the eyes
  • Do not give Flamazine to anyone else, even if they have similar problems to yours
Driving or using machines
  • Be careful before you drive or use any machines or tools until you know how Flamazine affects you
Drinking alcohol
  • Tell your doctor if you drink alcohol
Looking after your medicine
  • Keep Flamazine in a cool dry place away from light where the temperature stays below 25°C
  • Refrigeration is not normally needed but in temperatures in excess of 30°C some form of cooling is desirable

For more information, see Section 5. What should I know while using Flamazine? in the full CMI.

6. Are there any side effects?

Common less serious side effects include: nausea, vomiting, diarrhoea, skin rash, increasing pain, burning or itching. You may need urgent medical attention if you experience any of the following: red, raised bumps on the face and scalp, problems with urine volume or colour, heart pain, severe abdominal pain, inflammation of the blood vessels causing nodular swellings along length of vessel, allergy-type reactions such as blistering or angry red rash, skin discolouration, potentially life-threatening skin rashes. For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

Flamazine™

Active ingredient(s): silver sulfadiazine


Consumer Medicine Information (CMI)

This leaflet provides important information about using Flamazine. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Flamazine.

Where to find information in this leaflet:

1. Why am I using Flamazine?
2. What should I know before I use Flamazine?
3. What if I am taking other medicines?
4. How do I use Flamazine?
5. What should I know while using Flamazine?
6. Are there any side effects?
7. Product details

1. Why am I using Flamazine?

Flamazine contains the active ingredient silver sulfadiazine. Flamazine is a topical antibacterial cream with an active ingredient which belongs to the group of antibiotic medicines called sulfonamides.

Flamazine is used to prevent infection in severe burns. Other types of wounds, such as pressure sores and leg ulcers, may also benefit from the application of Flamazine cream.

It is soothing when applied and has proven activity against a broad range of organisms including both Gram-positive and Gram-negative bacteria and some viruses and fungi.

Your doctor may have prescribed Flamazine for another reason.

Ask your doctor if you have any questions about why Flamazine has been prescribed for you.

2. What should I know before I use Flamazine?

Warnings

Do not use Flamazine if:

  • you are allergic to silver sulfadiazine, or any medicine within the Sulfonamide group, or any of the ingredients listed at the end of this leaflet.
  • the tube or jar has been opened or shows signs of tampering before your first application
  • the expiry date (EXP) printed on the tube or jar has passed. If you use this medicine after the expiry date has passed, it may not work effectively.
  • always check the ingredients to make sure you can use this medicine.
  • do not give Flamazine to premature infants or newborn infants in the first months of life. Sulfonamides may cause a life-threatening condition known as “kernicterus” (jaundice of the brain) in babies during the first months of life by interfering with normal metabolism.

Check with your doctor if you:

  • have or have had any other medical conditions including:
    - low white blood cell count: a fall in white blood cell count has been demonstrated very occasionally, but it is not thought to be associated with the treatment. Nevertheless, regular blood counts are advisable if you are on long-term treatment.
    - problems with your liver and/or kidney:
    Flamazine should be used with caution in patients with poor liver or kidney function. Reaction to the cream can sometimes cause worsening in these areas but the incidence is lower than with other sulfonamides.
  • take any medicines for any other condition
  • have any allergies to any other medicines or any other substances, such as foods, preservatives or dyes
  • are glucose-6-phosphate deficient

Potentially life-threatening skin rashes (Stevens-Johnson Syndrome, toxic epidermal necrolysis) have been reported with the use of sulfadiazine, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk.

Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes).

These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin.

The highest risk for occurrence of serious skin reactions is within the first weeks of treatment.

If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of silver sulfadiazine, you must not be re-started on silver sulfadiazine at any time.

If you develop a rash or these skin symptoms, seek immediate advice from a doctor and tell him that you are taking this medicine.

If you have not told your doctor about any of the above, tell them before you use any Flamazine.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Flamazine should not be used during the last month of pregnancy. Your doctor will discuss the risks and benefits of using Flamazine when pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

Sulfonamides are excreted in the milk in small amounts and should be used with caution in breastfeeding mothers Your doctor will discuss the risks and benefits of using Flamazine when breast-feeding.

Do not apply Flamazine to the breasts before breast feeding.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with Flamazine and affect how it works.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Flamazine.

4. How do I use Flamazine?

How much to use

  • One jar or tube of Flamazine should be reserved for one person. If you are using jars, discard any remaining cream 24 hours after opening the jar. If you are using tubes, discard the product 7 days after opening.
  • Follow the instructions provided and use Flamazine until your doctor tells you to stop.
  • These directions may differ from the information contained in this leaflet.
  • If you do not understand the instructions, ask your doctor or pharmacist for help.

When to use Flamazine

  • Apply Flamazine at about the same time every day.
  • Flamazine should be applied by means of a sterile spatula or by hand, covered with a sterile glove, in a layer approximately 3-5 mm thick.
  • One application at least every 24 hours is normally sufficient but the number of times a day to apply the cream will depend on your own individual needs.
  • Where necessary reapply Flamazine to any area where it has been removed during activity.
  • It is important to apply Flamazine exactly as your doctor or pharmacist has told you. If you use it less often than you should, it may not work as well and your skin problem may not improve. Using it more often than you should may not improve your skin problem any faster and may cause or increase side effects.

How long to use Flamazine

  • Treatment is continued until healing is progressing satisfactorily or the burn site is ready for skin grafting.
  • Your doctor or pharmacist will tell you how long to keep applying Flamazine cream.
  • Do not use Flamazine for longer than your doctor tells you. If you use Flamazine for longer than your doctor or pharmacist tells you, the chance of side effects may increase.
  • If you are not sure how long to use Flamazine, talk to your doctor.

If you swallow Flamazine

Immediately telephone your doctor or Poisons Information Centre (telephone 13 11 26 in Australia / 0800 POISON or 0800 764 766 in NZ), or go to casualty at your nearest hospital, if you think that you or anyone else may have swallowed Flamazine. Do this even if there are no signs of discomfort or poisoning.

You may need urgent medical attention. Keep these telephone numbers handy.

If you use too much Flamazine

If you think that you have used too much Flamazine, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using Flamazine?

Things you should do

If you feel that Flamazine is not helping your condition, tell your doctor (or pharmacist).

Tell your doctor if, for any reason, you have not used Flamazine exactly as prescribed.

Otherwise, your doctor may think that it was not effective and change your treatment unnecessarily.

Call your doctor straight away if you:

  • become pregnant while using Flamazine

Remind any doctor, dentist or pharmacist you visit that you are using Flamazine.

Things you should not do

  • Do not use Flamazine in or near the eyes
  • Do not give Flamazine to anyone else, even if they have similar problems to yours

Things to be careful of

  • Do not use large amounts of Flamazine for a long time. If you use large amounts for a long time, the chance of absorption through the skin and the chance of side effects increases.
  • Ask your doctor or pharmacist if you are concerned about the length of time you have been using Flamazine.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how Flamazine affects you.

Drinking alcohol

Tell your doctor if you drink alcohol.

Looking after your medicine

  • Keep Flamazine in a cool dry place away from light where the temperature stays below 25°C.
  • Refrigeration is not normally needed but in temperatures in excess of 30°C some form of cooling is desirable.

Follow the instructions in the carton on how to take care of your medicine properly.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

When to discard your medicine (as relevant)

If your doctor tells you to stop using Flamazine or it has passed its expiry date, ask your pharmacist what to do with any that is left over.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Although these reactions are very rare, if you notice any signs and symptoms of serious skin reactions develop, immediately stop taking this medicine and seek urgent medical advice.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
Gut related:
  • Nausea
  • Vomiting
  • Diarrhoea
Skin:
  • Skin rash
  • Increasing pain
  • Burning or itching
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Autoimmune related:
  • Red, raised bumps on the face and scalp (lupus erythematosus)
Urinary:
  • Problems with urine volume or colour (renal or hepatic toxicity)
Heart related:
  • Heart pain (myocardititis)
Gastrointestinal:
  • Severe abdominal pain (pancreatitis)
Vascular:
  • Inflammation of the blood vessels causing nodular swellings along length of vessel (vasculitis, including polyarteritis nodosa)
Allergic reaction:
  • Allergy-type reactions such as blistering or angry red rash
Skin:
  • Skin discolouration
  • Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis)
Some bacteria and fungal infections (e.g. thrush) may be resistant to the effects of Flamazine and this could cause inflammation in burns wounds. Very occasionally an allergy can occur. If you experience redness and swelling you should consult your doctor.
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What Flamazine contains

Active ingredient
(main ingredient)
Silver Sulfadiazine 1% (10 mg/g)
Other ingredients
(inactive ingredients)
Propylene Glycol
Polysorbate 60
Polysorbate 80
Cetyl Alcohol
Glyceryl Monostearate
Paraffin Liquid
Purified Water
Potential allergensn/a

Do not take this medicine if you are allergic to any of these ingredients.

What Flamazine looks like

Flamazine is a sterile white cream. The cream is a semisolid oil in water emulsion.

FLAMAZINE 50g Tube (AUST R 159342)

FLAMAZINE 500g Jar (AUST R 159338)

Who distributes Flamazine

Flamazine is supplied in Australia by:

Smith & Nephew Pty. Ltd.
4 Drake Avenue,
Macquarie Park, NSW 2113
Phone: 02 9857 3999
Fax: 02 9857 3900

Flamazine is supplied in New Zealand by:

Smith & Nephew Ltd.
621 Rosebank Road, Avondale,
Auckland 1026
Phone: 09 828 4059
Fax: 09 820 2868

This leaflet was prepared in April 2024.

™Trademark of Smith & Nephew

Published by MIMS June 2024

BRAND INFORMATION

Brand name

Flamazine

Active ingredient

Silver sulfadiazine

Schedule

S4

 

1 Name of Medicine

Silver sulfadiazine.

2 Qualitative and Quantitative Composition

Composition.

Active ingredient.

Silver sulfadiazine 1.0% w/w.

Excipients.

For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Cream. White to off-white cream (semi-solid oil in water emulsion).

4 Clinical Particulars

4.1 Therapeutic Indications

Flamazine cream is indicated for the prevention of infection in severe burns. Other types of wounds, such as pressure sores and leg ulcers, may also benefit from the application of Flamazine cream.

4.2 Dose and Method of Administration

Method of administration.

To be applied topically.

Burns.

The burn wound should be cleaned and Flamazine cream applied over all the affected areas to a depth of 3-5 mm.
This application is best achieved with a sterile gloved hand and/or sterile spatula.
Where necessary, the cream should be reapplied to any area from which it has been removed by patient activity.
In burns, Flamazine cream should be reapplied at least every 24 hours, or more frequently if the volume of exudate is large.

Hand burns.

Flamazine cream can be applied to the burn and the whole hand enclosed in a clear plastic bag or glove which is then closed at the wrist. The patient should be encouraged to move the hand and fingers. The dressing should be changed when an excessive amount of exudate has accumulated in the bag.

Leg ulcers/ pressure sores.

The cavity of the ulcer should be filled with Flamazine cream to a depth of at least 3-5 mm. As Flamazine cream can cause maceration of normal skin on prolonged contact, care should be taken to prevent spread onto nonulcerated areas.
Application of Flamazine cream should be followed by an absorbent pad or gauze dressing, with further application of pressure bandaging as appropriate for the ulcer.
The dressings should normally be changed daily but for wounds which are less exudative, less frequent changes (every 48 hours) may be acceptable. Cleansing and debriding should be performed before application of Flamazine cream.
Flamazine cream is not recommended for use in leg or pressure ulcers that are very exudative.

Fingertip injuries.

Haemostasis of the injury should be achieved prior to the application of a 3-5 mm layer of Flamazine cream. A conventional finger dressing may be used. Alternatively the finger of a plastic or unsterile surgical glove can be used and fixed in place with waterproof adhesive tape. Dressings should be changed every 2-3 days.

4.3 Contraindications

As sulfonamides are known to cause kernicterus, Flamazine cream should not be used at, or near term pregnancy, on premature infants or on newborn infants during the first months of life. Flamazine cream is also contraindicated in patients known to be hypersensitive to silver sulfadiazine or to other components of the preparation such as cetyl alcohol or propylene glycol.

4.4 Special Warnings and Precautions for Use

Identified precautions.

Transient leucopenia has occurred although its association with application of Flamazine has not been confirmed. Nevertheless, regular blood counts are advisable in patients on long-term treatment.
Patients should be watched carefully for sensitivity, especially if there are known reactions to sulfonamides.
Local reactions have been reported in patients treated with silver sulfadiazine; the separation of the eschar may be delayed and fungal invasion of the wound may occur.
In patients with extensive burns, serum sulfonamide concentrations and renal function should be monitored and urine examined for sulfonamide crystals. Absorption of propylene glycol contained in the cream can affect serum osmolality which can interfere with some laboratory tests.
The use of Flamazine cream in some cases of glucose-6-phosphate dehydrogenase deficient patients may be hazardous as haemolysis may occur.
During treatment of burns over a large body area, significant amounts of silver sulfadiazine are systemically absorbed. Therefore, it is possible that any adverse reactions associated with sulfonamides may occur.
Life-threatening cutaneous reactions (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)) have been reported with the use of sulfadiazine. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment. If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Flamazine cream treatment should be discontinued. The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. If the patient has developed SJS or TEN with the use of silver sulfadiazine, silver sulfadiazine must not be re-started in this patient at any time.

Use in hepatic impairment/renal impairment.

Flamazine should be use with caution in patients with impaired renal or hepatic function. Sensitivity has been shown to occur but the incidence is lower than with other sulfonamides.

Use in the elderly.

Of the total number of subjects in clinical studies of silver sulfadiazine cream, seven percent were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Paediatric use.

Flamazine should not be used in premature infants or in newborn infants in the first months of life (see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy).

Effects on laboratory tests.

In the treatment of burn wounds involving extensive areas of the body, the serum sulfonamide derivative concentrations may approach adult therapeutic levels (8 mg% to 12 mg%). Therefore, in these patients it would be advisable to monitor serum sulfonamide concentrations. Renal function should be carefully monitored and the urine should be checked for sulfonamide crystals. Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

4.5 Interactions with Other Medicines and Other Forms of Interactions

As silver may inactivate enzymatic debriding agents, their concomitant use may be inappropriate.
In large area burns where serum sulfadiazine levels may approach therapeutic levels, it should be noted that the effects of systemically administered drugs may be altered.
This can especially apply to oral hypoglycaemic agents and to phenytoin. In the case of these drugs, it is recommended that blood levels should be monitored as their effects can be potentiated.

Cimetidine.

In patients with large area burns, it has been reported that coadministration of cimetidine may increase the incidence of leukopenia.
Sulfonamide may alter the effect of oral anticoagulants, methotrexate, and cyclosporine. There are isolated reports that sulfonamide may also interfere with the effectiveness of hormonal contraceptive.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data were available from studies in animals following topical administration of silver sulfadiazine. No treatment related effects on male or female fertility were documented following subcutaneous administration of silver sulfadiazine to rats at doses up to 500 mg/kg/day for two (females) or ten (males) weeks prior to mating.
(Category C)
Sulfonamides may cause kernicterus in babies during the first month of life by displacing bilirubin from plasma albumin. Sulfonamides should therefore be avoided as far as possible during the last month of pregnancy. Fetal findings (abdominal hernia and laevorotation of the heart) occurred in low incidence in rats at subcutaneous doses of ≥ 250 mg/kg/day during early embryonic development and organogenesis. The significance of these findings for clinical topical administration is unknown.
Flamazine should be used with caution in breastfeeding mothers. Systemically, sulfadiazine can be excreted in breast milk although at concentrations 15-35% of those found in serum.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Blood and lymphatic tissue disorders.

Common: leukopenia.
Leukopenia has been reported in 3-5% of burns patients treated with Flamazine. This may be a drug related effect, and often manifests itself 2-3 days after treatment has commenced. It is usually self limiting and therapy with Flamazine cream does not usually need to be discontinued, although the blood count must be monitored to ensure that it returns to normal within a few days.

General disorders and administration site conditions.

Common: application site burning.

Renal and urinary disorders.

Very rare: renal failure.

Skin and subcutaneous tissue disorders.

Common: pruritus.
Common: application site rash (including eczema and contact dermatitis).
Rare: argyria.
There is evidence that in large area wounds and/or after prolonged application, systemic absorption of silver can occur causing clinical argyria.
Very rare: severe cutaneous adverse reactions (SCARs), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (see Section 4.4).

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Not likely to occur with normal usage.
In extensively burned patients or in patients suspected of showing symptoms of excessive absorption, it is important to optimally maintain fluid balance, not only to prevent dehydration but also to avoid the possibility of renal failure.
If renal function is normal, fluids should be administered to maintain high urine output and assist in the rapid elimination of the drug.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Silver sulfadiazine is a sulfonamide and has broad antimicrobial activity against both Gram positive and Gram negative organisms.
Silver sulfadiazine acts on the cell membrane and cell wall. Unlike sulfadiazine or other sulfonamides, the antibacterial action of the silver salt of sulfadiazine does not appear to depend on inhibition of folic acid synthesis. Its action is not antagonised by p-aminobenzoic acid.
Silver sulfadiazine has broad antimicrobial activity against both Gram positive and Gram negative organisms including Pseudomonas aeruginosa, some yeasts and fungi. It has also been reported to be active in vitro against herpes virus and Treponema pallidum. Sulfonamides act by interfering with the synthesis of nucleic acids in sensitive micro-organisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid. Silver sulfadiazine has a bactericidal action; in contrast to sulfadiazine, the silver salt acts primarily on the cell membrane and cell wall and its action is not antagonised by p-aminobenzoic acid. Resistance to silver sulfadiazine has been reported and may develop during therapy.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Silver sulfadiazine is slowly metabolised in contact with wound exudates. Up to about 10% of the sulfadiazine may be absorbed; concentrations in blood of 10 to 20 microgram/mL have been reported although higher concentrations may be achieved when extensive areas of the body are treated. Some silver may be absorbed.
There is evidence that in large area wounds and/or after prolonged application, systemic absorption of silver can occur causing clinical argyria. The sulfadiazine readily diffuses across wounds and enters the general circulation. The degree of uptake will significantly depend upon the nature of the wound and the dosing regime. Sulfadiazine is excreted in the urine.

5.3 Preclinical Safety Data

Genotoxicity.

Silver sulfadiazine was not genotoxic in an in vitro bacterial reverse mutation assay or an in vivo mouse micronucleus test (PO administration), although the doses administered were considered low.

Carcinogenicity.

Long-term carcinogenicity studies of silver sulfadiazine have not been conducted. Silver sulfadiazine is well established in clinical practice in several countries over a number of decades without any grounds for suspicion of carcinogenic potential in humans.

6 Pharmaceutical Particulars

6.1 List of Excipients

Polysorbate 60 Ph. Eur, polysorbate 80 Ph. Eur, glyceryl monostearate Ph. Eur, cetyl alcohol Ph. Eur, liquid paraffin Ph. Eur, propylene glycol Ph. Eur and purified water Ph. Eur.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.
250 g and 500 g jars should be discarded 24 hours after opening. Tubes of Flamazine should be discarded 7 days after opening.

6.4 Special Precautions for Storage

Flamazine should be stored below 25°C. Protect from light. The contents of one container are for the treatment of one person.

6.5 Nature and Contents of Container

Cream: AUST R 159342.
20 g*, 50 g or 80 g* pre-printed cylindrical polyethylene tubes fitted with polypropylene caps.
Cream: AUST R 159338.
250 g* or 500 g black polypropylene jar fitted with a black polyethylene or polypropylene lid. All tubes and jars are tamper-evident.
* Pack sizes not marketed.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Silver sulfadiazine is a white or creamy white, odourless or almost odourless crystalline powder, which becomes yellow on exposure to light. Practically insoluble in water; slightly soluble in acetone; practically insoluble in alcohol, chloroform or ether; freely soluble in strong ammonia solution.

Chemical structure.


Chemical name: silver salt of N'-(pyrimidin-2-yl) sulfanilamide. C10H9AgN4O2S. M.W.: 357.1.

CAS number.

22199-08-2.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes